Search results
Showing 1081 to 1095 of 1422 results for social care
Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults.
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)
Evidence-based recommendations on aripiprazole for treating schizophrenia in young people aged 15 to 17.
In development [GID-TA10261] Expected publication date: TBC
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]
Discontinued [GID-TA10315]
Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]
Discontinued [GID-TA10324]
Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]
Discontinued [GID-HST10038]
In development [GID-TA10667] Expected publication date: TBC
Nintedanib for untreated malignant pleural mesothelioma [ID1424]
Discontinued [GID-TA10359]
Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)
Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events after myocardial infarction in adults.
Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]
Discontinued [GID-TA10464]
Venglustat for treating gangliosidoses in people 2 years and over ID 6358
In development [GID-TA11601] Expected publication date: TBC
NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
Discontinued [GID-TA10711]
Abicipar pegol for treating wet age-related macular degeneration ID1533
In development [GID-TA10511] Expected publication date: TBC
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]
Discontinued [GID-TA10763]